COMy 2022 | The role of imaging in myeloma
In this video, Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, discusses the role of imaging in the risk assessment of patients with myeloma, and further highlights functional imaging techniques including PET-CT and MRI and their place in myeloma. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Transcript (edited for clarity)
Imaging plays a very important role in multiple myeloma, mostly for staging the disease each time the disease is becoming active. But in the last years, it has been a growing role of imaging for risk assessment, both at diagnosis, but also in the evaluation of response after therapy.
When it comes to the risk assessment, we have to refer exclusively to functional imaging techniques, because they are the only one able to look at either disease metabolism, and this is PET-CT...
Imaging plays a very important role in multiple myeloma, mostly for staging the disease each time the disease is becoming active. But in the last years, it has been a growing role of imaging for risk assessment, both at diagnosis, but also in the evaluation of response after therapy.
When it comes to the risk assessment, we have to refer exclusively to functional imaging techniques, because they are the only one able to look at either disease metabolism, and this is PET-CT. Or at infiltration of the bone marrow and/or soft tissues, and this is MRI. So I may say that for sure, the two major players are PET-CT and MRI. And when it comes to MRI, especially with the diffusion-weighted imaging algorithm, which is adding a lot in particular in the evaluation of response after therapy.
Read more...
Disclosures
Honoraria and advisory board member for Janssen, Sanofi, BMS, Roche, Amgen, GSK, Pfizer
